13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001306923
Total reported value
$723.7M
$723.7M
49 檔
46.8%
During the Q4 2025 filing period, Palo Alto Investors LP (CIK: 0001306923) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $723.7M across 49 reported positions.
In Q4 2025, Palo Alto Investors LP displayed an active expansion posture, initiating 8 new positions and adding to 12 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | INSM | Insmed Inc | Stock-Healthcare | 11.86% | -4.29% | -0.47% | |
| 2 | AM6 | Amicus Therapeutics Inc | Stock-Other | 10.32% | -2.46% | EXIT | |
| 3 | PTCT | Ptc Therapeutics Inc | Stock-Healthcare | 9.56% | +0.76% | +4.79% | |
| 4 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 9.24% | +0.23% | +0.70% | |
| 5 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 6.17% | -0.52% | -1.03% | |
| 6 | ANAB | Anaptysbio Inc | Stock-Other | 4.66% | +0.22% | +2.45% | |
| 7 | BIIB | Biogen Inc | Stock-Healthcare | 4.50% | +0.24% | -1.13% | |
| 8 | DYN | Dyne Therapeutics Inc | Stock-Other | 4.01% | +0.48% | +16.59% | |
| 9 | UTHR | United Therapeutics CORP | Stock-Healthcare | 3.95% | -1.01% | — | |
| 10 | IRON | Disc Medicine Inc | Stock-Other | 3.51% | +0.28% | +41.53% | |
| 11 | IOVA | Iovance Biotherapeutics Inc | Stock-Other | 2.70% | -0.37% | -6.58% | |
| 12 | NVCR | NovoCure Limited | Stock-Healthcare | 2.34% | +0.55% | +3.41% | |
| 13 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 2.32% | -0.48% | +21.31% | |
| 14 | GOSS | Gossamer Bio Inc | Stock-Other | 1.93% | — | -18.17% | |
| 15 | CMPX | Compass Therapeutics Inc | Stock-Other | 1.89% | +0.53% | — | |
| 16 | PRTA | Prothena Corporation plc | Stock-Other | 1.76% | -0.25% | -0.27% | |
| 17 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 1.72% | +1.05% | +141.76% | |
| 18 | ANNX | Annexon Inc | Stock-Other | 1.67% | -0.17% | — | |
| 19 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 1.48% | +0.84% | +24.83% | |
| 20 | DNLI | Denali Therapeutics Inc | Stock-Other | 1.47% | -0.69% | EXIT | |
| 21 | CDNA | Caredx Inc | Stock-Other | 1.25% | +0.68% | +51.24% | |
| 22 | EHTH | Ehealth Inc | Stock-Other | 0.98% | +0.02% | -0.85% | |
| 23 | ALKS | Alkermes plc | Stock-Healthcare | 0.94% | +0.45% | +31.87% | |
| 24 | CAPR | Capricor Therapeutics Inc | Stock-Other | 0.91% | -0.31% | — | |
| 25 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.91% | +0.36% | -5.04% | |
| 26 | ALGN | Align Technology Inc | Stock-Healthcare | 0.90% | -0.36% | -9.22% | |
| 27 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 0.81% | -0.01% | -19.96% | |
| 28 | BCAX | Bicara Therapeutics Inc | Stock-Other | 0.70% | +0.59% | — | |
| 29 | NUVB | Nuvation Bio Inc | Stock-Other | 0.67% | -0.07% | -47.28% | |
| 30 | ACRS | Aclaris Therapeutics Inc | Stock-Other | 0.66% | +0.25% | — | |
| 31 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.60% | -0.03% | — | |
| 32 | TVTX | Travere Therapeutics Inc | Stock-Other | 0.59% | +0.27% | — | |
| 33 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 0.40% | +0.01% | — | |
| 34 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 0.36% | +0.06% | — | |
| 35 | STOK | Stoke Therapeutics Inc | Stock-Other | 0.32% | -0.04% | -31.69% | |
| 36 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 0.30% | +0.01% | — | |
| 37 | BNTX | Biontech Se-adr | Stock-Other | 0.26% | -0.02% | — | |
| 38 | ORKA | Oruka Therapeutics Inc | Stock-Other | 0.25% | -0.01% | — | |
| 39 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 0.22% | -0.02% | — | |
| 40 | PYXS | Pyxis Oncology Inc | Stock-Other | 0.17% | +0.13% | — | |
| 41 | ALDX | Aldeyra Therapeutics Inc | Stock-Other | 0.16% | +0.01% | — | |
| 42 | HUM | Humana Inc | Stock-Healthcare | 0.14% | +0.11% | — | |
| 43 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 0.11% | -0.02% | — | |
| 44 | CMPS | Compass Pathways PLC | Stock-Other | 0.11% | +0.13% | — | |
| 45 | URGN | UroGen Pharma Ltd. | Stock-Other | 0.08% | +0.05% | — | |
| 46 | ABEO | Abeona Therapeutics Inc | Stock-Other | 0.08% | +0.02% | — | |
| 47 | ✓ | Proqr Therapeutics N.v. | Stock-Other | 0.05% | — | — | |
| 48 | ✓ | Stock-Other | 0.01% | — | — | ||
| 49 | ✓ | Akari Therapeutics PLC | Stock-Other | 0.01% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | AM6 | Amicus Therapeutics Inc | +2.5% | -3.02% | Trim |
| 2 | DYN | Dyne Therapeutics Inc | +1.1% | +16.59% | Add |
| 3 | ANAB | Anaptysbio Inc | +0.8% | +2.45% | Add |
| 4 | MIRM | Mirum Pharmaceuticals Inc | +0.8% | +141.76% | Add |
| 5 | IRON | Disc Medicine Inc | +0.8% | +41.53% | Add |
| 6 | SNDX | Syndax Pharmaceuticals Inc | +0.5% | +21.31% | Add |
| 7 | CDNA | Caredx Inc | +0.4% | +51.24% | Add |
| 8 | DNLI | Denali Therapeutics Inc | +0.4% | +57.16% | Add |
| 9 | TSHA | Taysha Gene Therapies Inc | +0.2% | -5.04% | Trim |
| 10 | ACRS | Aclaris Therapeutics Inc | +0.1% | — | Unchanged |
| 11 | TVTX | Travere Therapeutics Inc | +0.1% | — | Unchanged |
| 12 | ORKA | Oruka Therapeutics Inc | +0.1% | — | Unchanged |
| 13 | URGN | UroGen Pharma Ltd. | 0% | — | Unchanged |
| 14 | ✓ | Akari Therapeutics PLC | 0% | — | Unchanged |
| 15 | ✓ | Proqr Therapeutics N.v. | 0% | — | Unchanged |
| 16 | NUVB | Nuvation Bio Inc | 0% | -47.28% | Trim |
| 17 | ABEO | Abeona Therapeutics Inc | 0% | — | Unchanged |
| 18 | HUM | Humana Inc | -0.1% | — | Unchanged |
| 19 | ALDX | Aldeyra Therapeutics Inc | -0.1% | — | Unchanged |
| 20 | ALKS | Alkermes plc | -0.1% | +31.87% | Add |
| 21 | EW | Edwards Lifesciences CORP | -0.1% | — | Unchanged |
| 22 | BCYC | Bicycle Therapeutics Plc-adr | -0.1% | — | Unchanged |
| 23 | BNTX | Biontech Se-adr | -0.1% | — | Unchanged |
| 24 | NBIX | Neurocrine Biosciences Inc | -0.1% | — | Unchanged |
| 25 | STOK | Stoke Therapeutics Inc | -0.1% | -31.69% | Trim |
| 26 | ALGN | Align Technology Inc | -0.2% | -9.22% | Trim |
| 27 | CRSP | CRISPR Therapeutics AG | -0.2% | — | Unchanged |
| 28 | PTCT | Ptc Therapeutics Inc | -0.2% | +4.79% | Add |
| 29 | EHTH | Ehealth Inc | -0.3% | -0.85% | Trim |
| 30 | PYXS | Pyxis Oncology Inc | -0.3% | — | Unchanged |
| 31 | BIIB | Biogen Inc | -0.3% | -1.13% | Trim |
| 32 | IOVA | Iovance Biotherapeutics Inc | -0.4% | -6.58% | Trim |
| 33 | ACAD | Acadia Pharmaceuticals Inc | -0.5% | +0.70% | Add |
| 34 | UTHR | United Therapeutics CORP | -0.6% | — | Unchanged |
| 35 | RARE | Ultragenyx Pharmaceutical In | -0.6% | +24.83% | Add |
| 36 | PRTA | Prothena Corporation plc | -0.6% | -0.27% | Trim |
| 37 | NVCR | NovoCure Limited | -0.7% | +3.41% | Add |
| 38 | GOSS | Gossamer Bio Inc | -0.7% | -18.17% | Trim |
| 39 | AGIO | Agios Pharmaceuticals Inc | -1.2% | -19.96% | Trim |
| 40 | INSM | Insmed Inc | -1.3% | -0.47% | Trim |
| 41 | BMRN | Biomarin Pharmaceutical Inc | -1.4% | -1.03% | Trim |
| 42 | ALNY | Alnylam Pharmaceuticals Inc | — | EXIT | Sold out |
| 43 | CMPX | Compass Therapeutics Inc | — | NEW | New buy |
| 44 | ANNX | Annexon Inc | — | NEW | New buy |
| 45 | CAPR | Capricor Therapeutics Inc | — | NEW | New buy |
| 46 | BCAX | Bicara Therapeutics Inc | — | NEW | New buy |
| 47 | RNAGBP | Avidity Biosciences Inc | — | EXIT | Sold out |
| 48 | XENE | Xenon Pharmaceuticals Inc | — | NEW | New buy |
| 49 | INSP | Inspire Medical Systems Inc | — | NEW | New buy |
| 50 | CMPS | Compass Pathways PLC | — | NEW | New buy |
According to official SEC Form 13F filings, Palo Alto Investors LP reported a total U.S. public equity portfolio value of $723.7M across 49 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including INSM, AM6, PTCT) accounted for 46.8% of total reported equity market value during Q4 2025.
Top New Position Initiated
CMPX
市值: $13.6M
Top Position Liquidated / Trimmed
ALNY
前期市值: $14.7M
During Q4 2025, Palo Alto Investors LP's top holdings by market value included INSM (11.9%)、AM6 (10.3%)、PTCT (9.6%). The largest single position, INSM, represented 11.9% of total portfolio value.
In Q4 2025, Palo Alto Investors LP made 36 total portfolio adjustments, initiating 8 new buys, adding to 12 positions, trimming 13 holdings, and fully liquidating 3 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.